𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Chronic Anemia and Fatigue in Elderly Patients: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Exploratory Study with Epoetin Alfa

✍ Scribed by Parag Agnihotri; Margaret Telfer; Zeeshan Butt; Abhay Jella; David Cella; Chris M. Kozma; Mukesh Ahuja; Shahbaz Riaz; Joseph Akamah

Book ID
109129706
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
156 KB
Volume
55
Category
Article
ISSN
0002-8614

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Randomized double-blind placebo-controll
Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study
✍ Gregory H. Pelton; Oliver L. Harper; Matthias H. Tabert; Harold A. Sackeim; Niko πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 97 KB πŸ‘ 2 views

## Abstract ## Objective To assess combined antidepressant and cognitive enhancer treatment in elderly patients presenting with depression plus cognitive impairment. ## Methods Twenty‐three elderly (>50 years old) depressed, cognitively impaired (DEP‐CI) patients participated in a pilot study. W

Rituximab in patients with primary progr
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 158 KB πŸ‘ 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro